Buy Generic Sustiva Online

Generic Sustiva Information

Introduction

Sustiva is a generic antiretroviral medication whose active compound is efavirenz, a non‑nucleoside reverse‑transcriptase inhibitor (NNRTI). It belongs to the anti‑viral drug group used for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. In the United Kingdom, Sustiva is prescribed as part of combination antiretroviral therapy (cART) to reduce viral load, restore immune function, and prevent disease progression. The medication is supplied by a range of certified manufacturers that meet UK Medicines and Healthcare products Regulatory Agency (MHRA) standards.

What is Sustiva?

Sustiva is the generic version of Stocrin, containing the same active compound efavirenz. Efavirenz was first approved by the European Medicines Agency (EMA) in 1999 and has become a cornerstone of first‑line therapy for many patients living with HIV. Our online pharmacy provides this generic alternative as a cost‑effective treatment option. Sustiva is formulated as film‑coated tablets that deliver a fixed dose of efavirenz, typically 600 mg per tablet. The product complies with Good Manufacturing Practice (GMP) and is listed in the UK’s National Health Service (NHS) formulary for the management of HIV infection.

How Sustiva Works

Efavirenz binds directly to the reverse‑transcriptase enzyme of HIV‑1, a protein required for the conversion of viral RNA into DNA. By occupying the enzyme’s active site, efavirenz blocks the polymerisation of viral DNA, halting replication of the virus within host cells. The inhibition is non‑competitive, meaning that the drug remains effective even when viral concentrations rise. After oral administration, efavirenz reaches peak plasma concentrations within 3–5 hours, and its long half‑life of approximately 40–55 hours allows once‑daily dosing. The drug is metabolised principally by cytochrome P450 2B6 (CYP2B6) and excreted in urine and feces.

Conditions Treated with Sustiva

• HIV‑1 infection (adult patients) – Sustiva is approved for use in combination with two nucleoside reverse‑transcriptase inhibitors (NRTIs) as part of cART. In the UK, an estimated 105 000 adults are living with diagnosed HIV, and sustained viral suppression markedly reduces morbidity and mortality.
• Pre‑exposure prophylaxis (PrEP) in selected regimens – Although not a primary indication, efavirenz‑based regimens have been explored in clinical trials for high‑risk populations.

Sustiva’s efficacy in lowering plasma HIV RNA to undetectable levels (< 50 copies/mL) has been demonstrated in pivotal phase III trials (e.g., the ACTG 5202 study). Its inclusion in the UK’s HIV treatment guidelines reflects robust evidence for improved immune recovery and reduced opportunistic infections.

Who is Sustiva For?

• Adults (≥ 18 years) with confirmed HIV‑1 infection who are initiating or maintaining cART and have no contraindications to efavirenz.
• Patients who require a once‑daily regimen with a high genetic barrier to resistance and who can tolerate the central nervous system (CNS) effects often associated with efavirenz.
• Individuals with co‑existing tuberculosis (TB) requiring rifampicin‑based therapy, as efavirenz dosing can be adjusted (increased to 800 mg) to offset the enzyme‑inducing effect of rifampicin.
• Patients who are not pregnant or who are in the second/third trimester, as efavirenz is contraindicated in early pregnancy due to potential fetal neural tube defects.

Sustiva may be unsuitable for patients with severe hepatic impairment, known hypersensitivity to efavirenz, or those taking strong CYP2B6 inhibitors (e.g., clopidogrel) that could raise drug concentrations and increase toxicity risk.

Risks, Side Effects, and Interactions

Common

• Central nervous system effects – dizziness, insomnia, vivid dreams, and headache.
• Gastrointestinal symptoms – nausea, abdominal pain, and diarrhoea.
• Skin reactions – mild rash or pruritus.

Rare

• Neuropsychiatric disorders – depression, anxiety, or suicidal ideation; patients with a history of mental health conditions should be monitored.
• Hepatotoxicity – transient elevation of hepatic transaminases; routine liver function tests are advisable.

Serious

• Severe skin reactions – Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate medical attention.
• Hypersensitivity reactions – angioedema, bronchospasm, or anaphylaxis.

Drug–Drug Interactions

• Rifampicin – induces CYP2B6, reducing efavirenz levels; dose increase to 800 mg may be needed.
• Nevirapine – co‑administration can increase neuropsychiatric toxicity; avoid concurrent use.
• Alcohol – may amplify CNS side effects; moderate consumption is recommended.
• St. John’s Wort – potent CYP2B6 inducer, potentially lowering efavirenz exposure.
• Contraceptive hormones – efavirenz may reduce the effectiveness of hormonal contraceptives; additional barrier methods should be considered.

Patients should disclose all concomitant medications, herbal products, and supplements to their healthcare professional before initiating Sustiva.

Practical Use: Dosing, Missed Dose, Overdose

• Standard adult dose – one tablet containing 600 mg efavirenz taken orally once daily, preferably on an empty stomach (at least 1 hour before or 2 hours after a meal) to optimise absorption.
• Missed dose – if a dose is forgotten within 12 hours, take it immediately; if more than 12 hours have elapsed, skip the missed dose and resume the regular schedule. Do not double‑dose.
• Overdose – ingestion of > 2 g may cause severe CNS depression, seizures, or coma. Seek emergency medical assistance promptly; treatment is symptomatic and supportive.
• Food and alcohol – high‑fat meals can increase efavirenz bioavailability and may heighten CNS effects; patients are advised to avoid large fatty meals when taking Sustiva. Alcohol should be limited to reduce additive neuropsychiatric risk.
• Comorbidities – dose adjustment is required for severe hepatic impairment (Child‑Pugh C). Renal function has minimal impact on efavirenz clearance.

Buying Sustiva from Our Online Pharmacy

Sustiva can be purchased from our online pharmacy in the UK. Our service offers:

• Affordable pricing – the generic tablet is supplied at near‑manufacturer cost, providing a significant saving compared with branded alternatives.
• Verified quality – all suppliers are MHRA‑approved and the tablets are stored under controlled conditions to preserve potency.
• Guaranteed delivery – discreet, reliable shipping with express options (delivery within 7 days) or standard airmail (approximately 3 weeks).
• Online‑only access – we operate as a pharmacy‑broker service, partnering with overseas licensed pharmacies that hold the requisite licences to ship internationally. This model enables a discreet service that respects patient privacy while ensuring regulatory compliance.

For patients who encounter barriers to obtaining antiretrovirals through traditional pharmacy channels or who lack insurance coverage, our platform provides a secure, cost‑effective alternative. All purchases are accompanied by a clear medication leaflet and a customer support line for post‑delivery queries.

FAQ

• What is the appearance of a Sustiva tablet?
  Sustiva tablets are film‑coated, round, and typically white to off‑white in colour. Each tablet is imprinted with “EFV 600” to denote the efavirenz dose of 600 mg.

• Can Sustiva be stored at temperatures above room temperature?
  The medication should be kept at 15–30 °C (59–86 °F). Prolonged exposure to heat above 30 °C may degrade the active ingredient and reduce efficacy.

• Is it safe to travel internationally with Sustiva?
  Yes, provided the medication is kept in its original packaging, stored in a cool, dry place, and accompanied by a copy of the prescription or a travel health letter where required by the destination country.

• Does Sustiva contain any listed allergens?
  In the UK formulation, the inert ingredients may include lactose and soy lecithin. Patients with known hypersensitivity should review the full ingredient list provided in the product leaflet.

• How does efavirenz differ from older NNRTIs such as nevirapine?
  Efavirenz has a longer half‑life, permitting once‑daily dosing, and it exhibits a higher genetic barrier to resistance. However, it is associated with more prominent CNS side effects compared with nevirapine.

• What were the key findings of the ACTG 5202 trial concerning efavirenz?
  The trial demonstrated that efavirenz‑based regimens achieved faster viral suppression and higher CD4⁺ cell count recovery than protease‑inhibitor‑based regimens in treatment‑naïve adults.

• Are there any special warnings for patients of Asian ethnicity?
  The CYP2B6*6 allele, more prevalent in certain Asian populations, can lead to higher efavirenz plasma concentrations, increasing the risk of neuropsychiatric adverse events. Dose adjustment or therapeutic drug monitoring may be considered.

• Can Sustiva be imported for personal use under UK law?
  Personal import of a three‑month supply of a prescribed medication is permitted under the UK’s “personal importation” provisions, provided the medication is for personal use and accompanied by a valid prescription.

• Does Sustiva influence results of drug‑of‑abuse testing?
  Efavirenz is not a controlled substance and does not typically appear on standard drug screening panels; however, it may be detected in specialized toxicology assays.

• What is the difference between EU and US formulations of efavirenz?
  EU‑sold tablets often contain a lower amount of excipients such as polyethylene glycol, whereas US versions may use different filler blends. Both conform to the same pharmacopoeial specifications for efavirenz content.

Glossary

Non‑nucleoside Reverse‑Transcriptase Inhibitor (NNRTI)

A class of antiretroviral drugs that bind directly to reverse‑transcriptase, blocking the conversion of viral RNA to DNA without mimicking nucleotides.

Cytochrome P450 2B6 (CYP2B6)

An enzyme in the liver that metabolises many drugs, including efavirenz. Genetic variations can affect drug clearance and toxicity risk.

Therapeutic Window

The range of drug concentrations in the blood that achieves optimal efficacy while minimising adverse effects.

⚠️ Disclaimer

The information provided about Sustiva is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Sustiva for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.